Prothena Corporation Investor Relations Material

Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery and development of novel therapies for diseases caused by protein dysregulation. The company's portfolio includes a range of investigational humanized antibodies and other therapeutic candidates targeting conditions such as AL amyloidosis, Parkinson's disease, ATTR amyloidosis, and Alzheimer's disease. Prothena's approach leverages insights into the biology of misfolded proteins to develop therapies aimed at changing the course of neurodegenerative and rare peripheral amyloid diseases. The company is headquartered in Dublin, Ireland, and its shares are listed on the Nasdaq.